-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagene Announces Investigator Initiated Phase 2 Trial For Neoadjuvant Muzastotug In Colorectal Cancer

Benzinga·02/27/2025 13:18:51
Listen to the news

- Trial to begin enrolling in April; expected primary completion in mid-2027 -

- Primary study endpoint of rate of major pathological response -

SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer.